Replication-defective adenovirus vectors were generated inoculated on day 0 with 10 5 II-45 cells into the pleural in which the gene of interest (lacZ, luciferase or HSV-tk) is cavity, received 7 × 10 9 infectious particles of IG.Ad. driven by the adenovirus major late promoter (MLP) or CMV.TK on day 1, day 2, day 4 or day 8. One day after the human cytomegalovirus immediate-early gene virus administration, 25 mg/kg GCV or PBS (controls) was promoter/enhancer (CMV). In vitro experiments with rat (IIinjected i.p. (intraperitoneally) twice daily. On day 15, all 45) and human (MERO 25) mesothelioma cell lines animals were killed. Significant tumor regression, equivalrevealed that the CMV promoter was stronger than the ent to 5 log cell kill, occurred in the treated rats suggesting MLP promoter regarding levels of expression of the luciferan impressive bystander effect. In a survival study, animals ase reporter gene and ganciclovir (GCV) killing efficiency were treated 9 days after inoculation of 10 5 tumor cells with after tk gene transfer. Following administration of IG.Ad.CMV.TK and a 14 days course of GCV. This treat-IG.Ad.CMV.lacZ recombinant adenovirus (Introgene, IG) ment prolonged symptom-free survival time from 19 days into the pleural cavity of Fischer rats with established in the controls to 33 days in the treated group. These mesothelioma, a widespread distribution of infectious virus responses can be best explained by assuming continued particles through the thorax contents was demonstrated.
Introduction
shown to be killed by this treatment while slowly repMalignant mesothelioma (MM) is a cancer of the mesolicating cells are less affected. 3 Thus, this strategy is conthelium most commonly occurring in the pleural cavity.
sidered appropriate for the treatment of solid tumors that Its incidence is related to exposure to asbestos.
1 MM has are invading normal tissues constituted predominantly of a very poor prognosis. Despite intensive treatment with slowly or nondividing cells such as gliomas. In animal surgery, radiation therapy, or chemotherapy, the average tumors effective transfer of the HSVtk gene has been achisurvival time is only 18-24 months from diagnosis. 2 eved with both recombinant adenovirus and recombinant Tumor growth is often limited to the thoracic cavity.
retrovirus. Retroviral vectors mediate stable integration Most patients die of local extension of the disease rather into the genome exclusively in dividing cells but this systhan of metastases. This growth pattern suggests that tem has the limitation of low viral titers and low trans-MM may be a good candidate for local treatment. duction efficiency. 4 To overcome this limitation, murine One potentially useful strategy of local treatment is HSVtk retrovirus-producer cells have been injected transduction of tumor cells in vivo with 'suicide' genes.
directly into the cerebrospinal fluid of animals with The most widely explored of these 'suicide' genes is the malignant leptomeningeal neoplasia 5 or into the tumor of herpes simplex virus thymidine kinase (HSVtk) gene. In rats carrying gliomas in the brain. 6, 7 Since this last stratthe presence of the thymidine kinase, ganciclovir (GCV) egy has proven to be effective, trials in human patients is phosphorylated to a toxic nucleotide analogue which with gliomas have been initiated. In contrast to retrovirus, adenovirus vectors have been shown to be efficient tools for local gene transfer in vivo. Obvious advantages leptomeningeal neoplasia, 10 mesothelioma 11 and in human tumors growing in immunodeficient mice, eg head and neck squamous cell cancer 12 and hepatocellular carcinoma. 13 In the current study we investigated the therapeutic potential of two recombinant adenoviruses using the adenovirus type 2 major late promotor (MLP) and the cytomegalovirus immediate-early promoter (CMV) respectively to drive the HSVtk gene. The CMV promoter has been found to be stronger than the MLP promoter in adenovirus harboring the p53 gene. 14 We were interested to know whether this difference would be reflected in more efficient cell kill after expression of the tk gene and treatment with GCV. The strength of the CMV promoter and the MLP promoter were compared by constructing vectors containing the luciferase gene and infecting human and rat mesothelioma cell lines with these vectors. The adeno-tk vectors were employed in combination with GCV to determine the cytotoxicity in vitro for both rat and human mesothelioma cell lines. Although the suicide effect was greater in vitro for the human cell line, we have used the rat mesothelioma for our in vivo studies. The human mesothelioma requires transplantation in immune deficient animals for in vivo studies. Since recent studies have suggested that cells transduced in vivo by adenovirus vectors are rapidly cleared by the immune system, 15 we preferred an immunocompetent animal model to study the in vivo potential of the suicide system because it mimics more closely the patient situation. The most effective of the two viruses, IG.Ad.CMV.TK, was used for treating mesotheliomas growing in the pleural cavity of rats. To study the distribution of transduced cells following intrapleural administration of recombinant adenovirus we applied an adenovirus vector encoding the lacZ gene under the control of the CMV promoter. We compared the results of the in vivo treatment of rat mesothelioma with those reported by Elshami et not clear whether that difference has to be ascribed to a more effective expression of the tk gene or to other factors, such as a faster growth rate of the mesothelioma in in both the human and the rat cell line after infection with the CMV vector than with the MLP vector, indicating a our laboratory. Other differences between the effects of the various viruses such as in vitro cytotoxicity and the stronger activity of the CMV promoter. reactions in normal tissues following injection into the pleural cavity are also discussed.
In In addition, the CMV promoter appeared to be more effective than the MLP promoter in driving HSVtk-IG.Ad.MLP.luc and IG.Ad.CMV.luc (Figure 1 ). With both recombinant vectors the luciferase activity measured in mediated GCV toxicity both in human and rat cell lines. The human MERO 25 cells were killed by GCV after human cells was 100-fold higher than the activity measured in rat cells. These observations suggest higher susceptibility transduction at a MOI of 1 with the IG.Ad.CMV.TK vector whereas a MOI of 10 was required for a similar of the human cells to infection by adenovirus vectors.
Furthermore, 10-fold higher expression was observed response with the IG.Ad.MLP.TK vector (Figure 2a and b). At the highest MOI (100) IG.Ad.MLP.TK induced only mals 1, 4, 8, 13 and 15 days after inoculation of 10 5 tumor cells into the pleural cavity. The tumor growth as measlimited GCV sensitivity in II-45 rat cells, while with IG.Ad.CMV.TK more than 90% cell kill was seen at an ured by the weight of the total thoracic organs is shown in Figure 3 . After 8 days, small disseminated tumor nod-MOI of 30 and a weak response at an MOI of 10 ( Figure  2c and d). These differences between the two promoters ules were visible in the pleural cavity but this was not reflected by an increased weight of the thoracic organs. are quantitatively similar to the difference of a factor of 10 observed following luciferase transductions (Figure 1) .
By the first time-point at which an increase was recorded, tumor growth was already apparent macroscopically The data in Figure 2 also reveal that in terms of MOI the rat cells are less permissive to transduction by both throughout the pleural cavity. At this point, day 13, the tumor mass has attained an average weight of 2.4 g recombinant viruses than the human cells; by a factor of 100 in the case of the CMV vector. Using the MLP vector which roughly represents 2.4 × 10 9 cells. Thus, during the first 13 days the inoculum of 10 5 tumor cells has this difference could not be calculated accurately because of the weak response of the rat cells at an MOI of 100, expanded 24 000-fold. This expansion requires at least between 14 and 15 cell doublings. Taking into account a but it is definitely more than 30-fold ( certain amount of tumor cell loss, the cell cycle time of this tumor has to be less than 1 day. For this and the In the human mesothelioma cells both recombinant viruses were cytotoxic in the absence of GCV. This effect following calculations we have disregarded the contribution of the stroma to the tumor weight, as the microwas less pronounced in the case of IG.Ad.MLP.TK. Neither of the two viruses were cytotoxic for cultured scopical inspection of these tumors shows an overwhelming predominance of mesothelioma cells ( Figure 4c ). rat cells at the MOIs tested, which may reflect the lower permissiveness of rat cells to adenovirus as compared Efficiency of in vivo gene transfer: To evaluate in vivo gene with human cells.
transfer efficiency and the distribution of the recombinant adenovirus through the thorax contents, 7 × 10 9 infectious In vivo studies units of IG.Ad.CMV.lacZ were injected intrapleurally into rats bearing 1-or 10-day-old malignant mesotheliomas. Tumor growth rate: The tumor growth characteristics of II-45 cells in F344 rats were determined by killing the aniControl animals received IG.Ad.CMV. TK. Three days after virus injection, the rats were killed and the thoracic cavity stained with X-gal solution to monitor lacZ expression. At the time of death the tumors had been growing for 4 and 13 days, respectively. In the former group, macroscopical tumors could not be found, but at day 13 the thoracic cavity contained a large tumor mass. In both groups of rats the parietal and visceral pleura were stained uniformly blue. Microscopic inspection of paraffin sections showed a homogeneous distribution of blue cells in the mesothelium (Figure 4a and b) . In the day 13 group a patchy distribution of blue cells mostly in the superficial cell layers of the tumor tissue was observed (Figure 4c ). The pleural surfaces were normal, no inflammatory reaction of the mesothelium was observed. After confirmation of the susceptibility of HSVtk expressing mesothelioma cells to GCV exposure in vitro, we investigated the effect of administration of the IG.Ad.CMV.TK virus followed by treatment with GCV and subsequently received GCV, presented small tumor deposits in several sites within the thoracic cavity. Howin pleural mesotheliomas in rats. After inoculation of 10 5 II-45 cells into the right pleural cavity on day 0, groups ever, these tumor masses were much smaller than the ones found in the control group receiving PBS, as is of four rats received a single injection of 7 × 10 9 infectious particles at the site of tumor inoculation either on day 1, reflected in the weight of the thoracic contents (groups 4 and 8 respectively, Table 1 ). These small tumor deposits 2, 4 or 8, respectively. One day after the injection of the virus, i.p. treatment with GCV was started until the anicould not be dissected out accurately, so that the total weight could not be estimated. An approximation is promals were killed on day 15. The macroscopical appearance and the weight of the thoracic contents are listed in vided by subtracting the average thoracic content weight of groups 1 to 3 (3.03 g) from that of group 4, which Table 1. In the animals of groups 1, 2 and 3 macroscopic tumor growth was not observed inside the thorax, but in yields 0.17 g. The treated animals did not show any clinical abnormalities at any time during the treatment. The five out of 12 rats tumor was present in the scar of the thoracotomy. This may be due to leakage of tumor cells pleural surfaces of these animals were macroscopically normal, but microscopic inspection revealed a mild into the wound bed. Presently, we have replaced the thoracotomy by needle injection into the pleural cavity; this inflammatory reaction of the mesothelium with fibrosis and infiltration by macrophages and lymphocytes (Figure procedure minimizes tumor growth in scar tissue. The animals that were treated with IG.Ad.CMV.TK at day 8 5) . This reaction was seen in both the parietal and the Tumor only present in the scar of the thoracotomy.
trols. As a result of the treatment with GCV the symptom-free survival was significantly prolonged to 33 ± 1.8 days as compared to 19.2 ± 1.2 days ( Figure 6 , log rank test P Ͻ 0.004). The tumor weight at the time of death as calculated from comparison of the weights of the thoracic contents with that of age-matched nontumor bearing animals was 2.9 ± 1.1 g in the GCV treated rats and 4.4 ± 0.8 g in the controls, the difference being not statistically significant.
Discussion
The in vitro data indicate that the CMV vectors (IG.Ad.CMV.luc, IG.Ad.CMV.TK) are about 10-fold more effective than the respective MLP vectors in the induction of luciferase expression and in inducing sensitivity to GCV-mediated toxicity. The latter suggests higher expression levels of tk following infection with the CMV virus. A similar difference was reported by Wills et al 14 for vectors carrying the p53 gene with the CMV and the MLP promoter, respectively. The CMV virus, as well as the MLP virus, exhibited cytotoxicity in the absence of GCV for the human cell line.
Figure 5 Histologic section of the mesothelium after treatment with IG.Ad.CMV.TK/GCV. (a) Heart and pericardium of a rat treated with IG.Ad.CMV.TK on day 2, followed by treatment with GCV until death on day 14 (HPS stained, × 400). (b) Heart and pericardium of a nontreated animal (HPS stained, × 400).
visceral pleura as well as in the pericardium. In the animals treated with PBS the pleurae were completely infiltrated with tumor tissue, so that it could not be established whether the inflammation noted in the GCV treated animals was caused by the recombinant virus or the combination of GCV and recombinant virus.
Survival following treatment with IG.Ad.CMV.TK and following day in one group and continued for 14 days.
Log-rank statistical analysis revealed that the two survival curves were different (P Ͻ 0.04).
The other group was treated with PBS and served as con-Again, based on MOI the CMV virus was more toxic than group 4 were exposed to GCV at day 9. As was calculated in the Results section, at day 15 tumor weight was 0.17 the MLP virus. The viruses were not toxic for rat cells but this may well be due to the lower susceptibility of rat cells g that is equivalent to 1.7 × 10 8 tumor cells. Based on this last point, a regrowth curve was constructed for the to infection by adenovirus, which we found to be about 100-fold for all the various end points studied (Figures 1 treated rats of group 4, Table 1 (Figure 7, curve B) . The fraction of tumor cells killed by the treatment can be caland 2). We have observed a similar dose-dependent toxic effect of adeno-tk virus in other human cell lines including: culated assuming an immediate cytotoxic effect on day 9 followed by a regrowth at the same rate as represented glioma cells (U251), small cell lung carcinoma cells (GLC-01), non-small cell lung carcinoma cells (A549) and melaby the growth curve for nontreated tumors (Figure 7 , curve A) and comparing the number of cells for both noma cells (518 A2), but not in the rat glioma cell line 9L. 16 This toxic effect seems to be related to the levels of curves on day 9. By these means of comparison the result of the treatment can be expressed as about 5 log cell kill. expression of the transgene in the infected cells; we also observed cytotoxicity related to higher expression of the The tumor growth curve of the treated animals in this experiment has shifted 9.7 days (Figure 7, curve B) . lacZ gene after recombinant adenovirus infection of human cells. 16 It is important to know whether these cytotoxic Accordingly these animals were expected to die on day 29. If we compare this with the survival time of the rats effects in vitro have relevance for the clinical use of adenoviral vectors for gene therapy. In the present study, we treated for 14 days with GCV ( Figure 6 ), the latter animals survived for 33 days, that is 4 days longer than observed a mild inflammation of the normal mesothelium after treatment with IG.Ad.CMV.TK and GCV. This process expected. Since the only difference was the longer exposure to GCV it has to be assumed that the tumor is not related to tumor growth because it was also observed in animals without tumor that received the same treatment.
response is determined by the duration of the GCV treatment. It is therefore worth investigating longer exposure This reaction could be caused by overexpression of the tk gene. More extensive toxicity studies are clearly needed to times than presently employed. Apart from this issue, the tumor response in our survival experiment seems to sigelucidate whether this reaction is caused by the recombinant adenovirus, the GCV or the combination of both nificantly exceed expectations based on the distribution of the transduced cells as demonstrated with the lacZ agents. More relevant is whether this treatment-related inflammation will occur in patients. The only way to invesrecombinant virus. In that experiment only a few per cent of the tumor cells were transduced. Apparently, the sotigate this issue is dose-finding studies in patients.
The results of the two in vivo experiments using suicide called bystander effect in this tumor is much greater than so far assumed. It seems unlikely that the bystander effect gene therapy provide some data to evaluate the resulting tumor inhibition in a quantitative way. Firstly, a theoreticould persist beyond the few days of GCV treatment. By that time the vast majority of transduced tumor cells cal growth curve can be constructed based on three measured tumor weights obtained at day 13: 2.4 g, day 15 :
should have entered cell division with suicide as a consequence. Then, the only other source of thymidine kinase 4.6 g (both from Figure 3 : weight of thoracic organs of tumor-bearing rats minus weight of thoracic organs of to produce phosphorylated GCV is nondividing transduced cells. Such cells could be tumor cells that are rats 1 day after injection of tumor cells) and day 19: 4.4 g (from survival experiment data, control group). These are resting. Alternatively as we observed that a large proportion of normal mesothelium cells were also transconverted to number of tumor cells considering 1 g equal to 10 9 cells. The other informative point is the inoculum duced in the lacZ experiment (Figure 4a and b) , it is tempting to speculate that these cells are an additional of 10 5 tumor cells at day 0. A Gompertz-fitted growth curve 17 was estimated using these points ( Figure 7 , curve and long-lasting source of toxic GCV metabolites that can be transfered to nontransduced tumor cells. Another A). In the experiment described in Table 1 the rats of hypothesis could be an immunological reaction against the tumor. These issues are presently under investigation. Our in vivo results largely confirm the data published recently by Elshami et al 11 on treatment of MM. However, there are some differences. First, we found a longer survival time after treatment with IG.Ad.CMV.TK/GCV, 14 days against 8 days reported by Elshami et al. 11 Moreover, we did not observe differences in tumor weight at the time of death in our survival study while Elshami et al reported lower tumor weights in the treated animals. Both groups of investigators used the same tumor model, similar techniques for implantation of the tumor cells and treated similar tumor sizes. However Elshami et al 11 started the treatment 4 days after injection of 10 6 II-45 cells and in our case we started 8 days after injection of 10 5 cells. Apparently, the growth characteristic of the tumor is different between the two groups. In our hands the tumor cell doubling time is about 24 h while for Elshami et al it is longer, approximately 2 days. This discrepancy could explain why we did not find a marked difference in tumor weight at the time compare them since the procedures for determining virus titers were different. The recombinant adenovirus vectors are also different: in our case the promoter that drives the HSVtk gene is the CMV promoter and Elshami et al used a construct with the RSV (Rous Sarcoma virus) promoter. Moreover, we retained in our vector the E3 region whose function in the wild-type virus is to evade an immune response against infected cells. This may have caused longer HSV-tk expression and may have resulted in more effective therapy. We can not provide a conclusive explanation for the observed difference in outcome between the two laboratories. Both the different vectors as well as the faster tumor growth may have contributed to the higher sensitivity of the tumor cells to the HSV-tk/GCV treatment in our hands.
Clearly, the responses observed in the present experiments were obtained with tumor masses that are many orders of magnitude smaller than those to be encountered in patients with MM. On the other hand, human tumor cells seem to be more permissive to adeno-tk. In analogy with the strategy successfully developed for con- IG.Ad.CMV.TK at MOI of 0, 1, 3, 10, 30 and 100, respectGibco, Breda, The Netherlands). All cell lines were mainively. The culture medium in each well was replaced with tained at 37°C in a humidified atmosphere at 5% CO 2 .
medium 24 h later with or without 10 m of GCV (Syntex BV, Rijswijk, The Netherlands). After 72 h the cells in the Adenovirus vectors control wells (MOI 0, without GCV) were counted and The construction of IG.Ad.MLP.TK and IG.Ad.MLP.luc diluted in order to seed 200 cells in a 60 mm culture dish have been described in detail elsewhere.
7,10 IG.Ad.CMV.TK (Costar). The same dilutions were made for the cells of the was made from the pCMV.TK plasmid (Figure 8 ), in which other wells, thus identical volumes were placed in 60 mm the HSV-tk expression is under the control of the CMV prodishes and the cells were cultured using the same conmoter and SV40 RNA splicing signals (180 bp) containing ditions as described previously. After 8-10 days, dishes splice donor and acceptor signals of the late viral genes 16s
were fixed with methanol (70% solution) and stained with and 19s. These sequences were isolated from pCMV a methylene blue solution; macroscopic colonies (more than NLS/lacZ, 19 obtained from Dr Fortunati (Erasmus Univer-50 cells) were counted. sity, Rotterdam, The Netherlands). The Escherichia coli lacZ marker gene preceded by a nuclear location signal and the In vivo protocols luciferase gene were cloned in plasmids similar to MM were established in syngeneic Fisher 344 rats (11-pCMV.TK called pCMV.LacZ and pCMV.luc respectively.
week-old, males, weighing 250-360 g) by injecting 10 5 IIThe adenovirus vectors IG.Ad.CMV.TK, IG.Ad.CMV.LacZ 45 cells suspended in 500 l PBS into the pleural cavity and IG.Ad.CMV.luc were generated by cotransfecting 293 via thoracotomy between the eighth and ninth ribs at the cells with SalI linearized plasmids and the large ClaI fraglateral side of the right thorax. To evaluate the tumor ment of wild-type Ad5 DNA. Recombinant adenovirus growth rate, animals were killed 1, 4, 8, 13 or 15 days were plaque-purified twice, propagated and titrated accordafter injection of the tumor cells, and the thoracic contents ing to standard procedures. The virus titers were determi-(lungs, heart, mediastinum, trachea, and diaphragm) nated by end point cytopathogenic effect (CPE) assay. 
